RU2007143053A - Применение селективных модуляторов хлорных каналов для лечения алкогольной и/или стимуляторной токсикомании - Google Patents
Применение селективных модуляторов хлорных каналов для лечения алкогольной и/или стимуляторной токсикомании Download PDFInfo
- Publication number
- RU2007143053A RU2007143053A RU2007143053/15A RU2007143053A RU2007143053A RU 2007143053 A RU2007143053 A RU 2007143053A RU 2007143053/15 A RU2007143053/15 A RU 2007143053/15A RU 2007143053 A RU2007143053 A RU 2007143053A RU 2007143053 A RU2007143053 A RU 2007143053A
- Authority
- RU
- Russia
- Prior art keywords
- selective
- modulator
- channel modulator
- patient
- chlorine channel
- Prior art date
Links
- 108010062745 Chloride Channels Proteins 0.000 title claims abstract 20
- 102000011045 Chloride Channels Human genes 0.000 title claims abstract 20
- 238000011282 treatment Methods 0.000 title claims abstract 9
- 230000004936 stimulating effect Effects 0.000 title claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title abstract 4
- 238000000034 method Methods 0.000 claims abstract 21
- OFBIFZUFASYYRE-UHFFFAOYSA-N flumazenil Chemical compound C1N(C)C(=O)C2=CC(F)=CC=C2N2C=NC(C(=O)OCC)=C21 OFBIFZUFASYYRE-UHFFFAOYSA-N 0.000 claims abstract 9
- 229960004381 flumazenil Drugs 0.000 claims abstract 8
- 150000001875 compounds Chemical class 0.000 claims abstract 5
- 201000009032 substance abuse Diseases 0.000 claims abstract 4
- 231100000736 substance abuse Toxicity 0.000 claims abstract 4
- 208000011117 substance-related disease Diseases 0.000 claims abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 3
- 230000000694 effects Effects 0.000 claims abstract 2
- 102000005915 GABA Receptors Human genes 0.000 claims 7
- 108010005551 GABA Receptors Proteins 0.000 claims 7
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 6
- 229940125516 allosteric modulator Drugs 0.000 claims 5
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 claims 4
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims 4
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims 4
- 230000001225 therapeutic effect Effects 0.000 claims 4
- OOBHFESNSZDWIU-GXSJLCMTSA-N (2s,3s)-3-methyl-2-phenylmorpholine Chemical compound C[C@@H]1NCCO[C@H]1C1=CC=CC=C1 OOBHFESNSZDWIU-GXSJLCMTSA-N 0.000 claims 2
- SHXWCVYOXRDMCX-UHFFFAOYSA-N 3,4-methylenedioxymethamphetamine Chemical compound CNC(C)CC1=CC=C2OCOC2=C1 SHXWCVYOXRDMCX-UHFFFAOYSA-N 0.000 claims 2
- 239000003477 4 aminobutyric acid receptor stimulating agent Substances 0.000 claims 2
- 229940121909 GABA receptor agonist Drugs 0.000 claims 2
- -1 MDA Chemical compound 0.000 claims 2
- 230000001476 alcoholic effect Effects 0.000 claims 2
- 229940025084 amphetamine Drugs 0.000 claims 2
- 229960003920 cocaine Drugs 0.000 claims 2
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 claims 2
- 229960000632 dexamfetamine Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229960002179 ephedrine Drugs 0.000 claims 2
- 229960002870 gabapentin Drugs 0.000 claims 2
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 claims 2
- 229960000930 hydroxyzine Drugs 0.000 claims 2
- KLNFAMGHSZQYHR-UHFFFAOYSA-N imidazo[4,5-i][1,2]benzodiazepine Chemical class C1=CC=NN=C2C3=NC=NC3=CC=C21 KLNFAMGHSZQYHR-UHFFFAOYSA-N 0.000 claims 2
- 150000002500 ions Chemical class 0.000 claims 2
- 229960001252 methamphetamine Drugs 0.000 claims 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 claims 2
- 238000012544 monitoring process Methods 0.000 claims 2
- 229960003209 phenmetrazine Drugs 0.000 claims 2
- 230000035945 sensitivity Effects 0.000 claims 2
- 235000019156 vitamin B Nutrition 0.000 claims 2
- 239000011720 vitamin B Substances 0.000 claims 2
- HZABUXCSZMLBHU-UHFFFAOYSA-N 1H-1,4-benzodiazepine-3-carboxylic acid Chemical compound C1=NC(C(=O)O)=CNC2=CC=CC=C21 HZABUXCSZMLBHU-UHFFFAOYSA-N 0.000 claims 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 1
- 230000003281 allosteric effect Effects 0.000 claims 1
- 235000005550 amino acid supplement Nutrition 0.000 claims 1
- 238000009226 cognitive therapy Methods 0.000 claims 1
- 230000037213 diet Effects 0.000 claims 1
- 235000005911 diet Nutrition 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 238000009207 exercise therapy Methods 0.000 claims 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 1
- 238000002483 medication Methods 0.000 claims 1
- 229940075993 receptor modulator Drugs 0.000 claims 1
- 229940046001 vitamin b complex Drugs 0.000 claims 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 abstract 1
- 235000019788 craving Nutrition 0.000 abstract 1
- 239000003368 psychostimulant agent Substances 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/111,435 US20050192271A1 (en) | 2003-07-15 | 2005-04-21 | Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse |
| US11/111,435 | 2005-04-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2007143053A true RU2007143053A (ru) | 2009-05-27 |
Family
ID=37215204
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007143053/15A RU2007143053A (ru) | 2005-04-21 | 2006-04-07 | Применение селективных модуляторов хлорных каналов для лечения алкогольной и/или стимуляторной токсикомании |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US20050192271A1 (https=) |
| EP (1) | EP1742639B1 (https=) |
| JP (1) | JP2008536921A (https=) |
| KR (1) | KR20080004615A (https=) |
| CN (1) | CN101203225A (https=) |
| AT (1) | ATE539755T1 (https=) |
| AU (1) | AU2006240324B2 (https=) |
| BR (1) | BRPI0610038A2 (https=) |
| CA (1) | CA2605918A1 (https=) |
| CR (1) | CR9444A (https=) |
| IL (1) | IL186641A0 (https=) |
| MX (1) | MX2007012993A (https=) |
| NO (1) | NO20075562L (https=) |
| NZ (1) | NZ562585A (https=) |
| RU (1) | RU2007143053A (https=) |
| WO (1) | WO2006115743A2 (https=) |
| ZA (1) | ZA200709048B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050192271A1 (en) * | 2003-07-15 | 2005-09-01 | Hythiam, Inc. | Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse |
| RU2468799C1 (ru) * | 2011-08-03 | 2012-12-10 | Общество с ограниченной ответственностью "Урал Крафт" | Способ купирования алкогольного абстинентного синдрома посредством блокады бензодиазепиновых рецепторов |
| WO2015054730A1 (en) * | 2013-10-14 | 2015-04-23 | Palmaya Pty Ltd | Compositions and methods of administering same |
| US20200143922A1 (en) * | 2016-06-03 | 2020-05-07 | Yale University | Methods and apparatus for predicting depression treatment outcomes |
| JP2021521103A (ja) * | 2018-04-06 | 2021-08-26 | オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 物質使用障害の処置におけるガボキサドールの使用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5028611A (en) * | 1989-06-29 | 1991-07-02 | The Regents Of The University Of Minnesota | Treatment for cocaine use |
| US5519017A (en) * | 1990-03-29 | 1996-05-21 | Lts Lohmann Therapie-Systeme Gmbh + Co. Kg | Pharmaceutic formulation for the treatment of alcoholism |
| SE9100860D0 (sv) * | 1991-03-22 | 1991-03-22 | Kabi Pharmacia Ab | New use |
| DE4123106A1 (de) * | 1991-07-09 | 1993-01-14 | Schering Ag | Arzneimittel zur behandlung von entzugssymptomen |
| US5229120A (en) * | 1992-02-05 | 1993-07-20 | Devincent James F | Treatment for cocaine abuse |
| US5792796A (en) * | 1994-07-27 | 1998-08-11 | Warner-Lambert Company | Methods for treating anxiety and panic |
| GB9420010D0 (en) * | 1994-10-01 | 1994-11-16 | Marck Sharp & Dohme Limited | Nucleic acids |
| ID26346A (id) * | 1998-03-31 | 2000-12-14 | Shionogi & Co | PROSES PEMBUATAN TURUNAN ASAM 5-HIDROKSIBENZO (b)TIOFEN-3-KARBOKSILAT |
| AU4100699A (en) | 1998-05-28 | 1999-12-13 | Sepracor, Inc. | Compositions and methods employing r(-) fluoxetine and other active ingredients |
| US6890951B2 (en) * | 1998-08-05 | 2005-05-10 | Brookhaven Science Associates Llc | Treatment of addiction and addiction-related behavior |
| US6541520B1 (en) * | 1998-08-05 | 2003-04-01 | Brookhaven Science Associates | Treatment of addiction and addiction-related behavior |
| US6339106B1 (en) * | 1999-08-11 | 2002-01-15 | Sepracor, Inc. | Methods and compositions for the treatment and prevention of sexual dysfunction |
| EP1133299A1 (en) * | 1998-11-23 | 2001-09-19 | Sepracor Inc. | 2-hydroxymethylolanzapine compositions and methods |
| US6489341B1 (en) * | 1999-06-02 | 2002-12-03 | Sepracor Inc. | Methods for the treatment of neuroleptic and related disorders using sertindole derivatives |
| US6399826B1 (en) * | 1999-08-11 | 2002-06-04 | Sepracor Inc. | Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain |
| US6750235B1 (en) * | 1999-09-30 | 2004-06-15 | The General Hospital Corporation | Pramipexole as a treatment for cocaine craving |
| EP1125579A3 (en) * | 2000-01-18 | 2003-01-02 | Pfizer Products Inc. | Uses of agrp-melanocortin receptor binding modulating compounds |
| KR100712570B1 (ko) * | 2001-01-17 | 2007-05-02 | 하이디엄, 인크. | 알콜 의존성 치료약의 제조에서 플루마제닐의 용도 |
| US20050192271A1 (en) * | 2003-07-15 | 2005-09-01 | Hythiam, Inc. | Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse |
| CA2436511C (en) * | 2001-02-15 | 2009-08-04 | Juan Jose Legarda Ibanez | Use of flumazenil to produce a medicament for the treatment of cocaine dependency |
| US20020150632A1 (en) * | 2001-04-12 | 2002-10-17 | Nick Scott | Psychonutracological method for craving reduction in humans |
| FR2827172B1 (fr) * | 2001-07-13 | 2004-07-02 | Pf Medicament | Derives de pyridin-2-yl-methylamine pour le traitement de la dependance aux opioides |
| US20030176456A1 (en) * | 2001-12-21 | 2003-09-18 | June Harry L. | Methods for reducing alcohol cravings in chronic alcoholics |
| US6740677B2 (en) * | 2002-08-19 | 2004-05-25 | Hong Xue | Methods of treating benzodiazepine site (BZD-S) associated syndromes using 2′ hydroxyflavonoids |
| AU2004216360B2 (en) * | 2003-02-27 | 2009-09-17 | Eisai R & D Management Co., Ltd. | Pharmaceutical composition for treatment of drug dependence |
| CA2526101A1 (en) * | 2003-05-30 | 2004-12-23 | Titan Pharmaceuticals, Inc. | Implantable polymeric device for sustained release of nalmefene |
| JP2005332453A (ja) * | 2004-05-19 | 2005-12-02 | Hitachi Ltd | 情報再生装置及び情報再生方法 |
| US20060167723A1 (en) * | 2005-01-21 | 2006-07-27 | Berg L M | Method of treating dependencies |
| JP2008538748A (ja) | 2005-04-07 | 2008-11-06 | ハイシアム， インコーポレイテッド | 不安、物質乱用及び依存の予防のための改良型方法及び組成物 |
-
2005
- 2005-04-21 US US11/111,435 patent/US20050192271A1/en not_active Abandoned
-
2006
- 2006-04-07 AU AU2006240324A patent/AU2006240324B2/en not_active Ceased
- 2006-04-07 CN CNA2006800219633A patent/CN101203225A/zh active Pending
- 2006-04-07 KR KR1020077026998A patent/KR20080004615A/ko not_active Withdrawn
- 2006-04-07 BR BRPI0610038A patent/BRPI0610038A2/pt not_active IP Right Cessation
- 2006-04-07 MX MX2007012993A patent/MX2007012993A/es not_active Application Discontinuation
- 2006-04-07 EP EP06740763A patent/EP1742639B1/en not_active Expired - Lifetime
- 2006-04-07 WO PCT/US2006/013155 patent/WO2006115743A2/en not_active Ceased
- 2006-04-07 JP JP2008507703A patent/JP2008536921A/ja active Pending
- 2006-04-07 RU RU2007143053/15A patent/RU2007143053A/ru not_active Application Discontinuation
- 2006-04-07 AT AT06740763T patent/ATE539755T1/de active
- 2006-04-07 CA CA002605918A patent/CA2605918A1/en not_active Abandoned
- 2006-04-07 NZ NZ562585A patent/NZ562585A/en not_active IP Right Cessation
-
2007
- 2007-10-14 IL IL186641A patent/IL186641A0/en unknown
- 2007-10-16 CR CR9444A patent/CR9444A/es not_active Application Discontinuation
- 2007-10-19 ZA ZA200709048A patent/ZA200709048B/xx unknown
- 2007-11-05 NO NO20075562A patent/NO20075562L/no not_active Application Discontinuation
-
2008
- 2008-05-13 US US12/119,911 patent/US7863267B2/en not_active Expired - Lifetime
-
2009
- 2009-03-13 US US12/404,132 patent/US20090215751A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1742639A2 (en) | 2007-01-17 |
| AU2006240324B2 (en) | 2010-02-25 |
| MX2007012993A (es) | 2008-03-11 |
| CA2605918A1 (en) | 2006-11-02 |
| NZ562585A (en) | 2010-04-30 |
| EP1742639A4 (en) | 2008-05-07 |
| CR9444A (es) | 2008-02-20 |
| US20050192271A1 (en) | 2005-09-01 |
| WO2006115743A3 (en) | 2007-06-28 |
| US20090215751A1 (en) | 2009-08-27 |
| US7863267B2 (en) | 2011-01-04 |
| CN101203225A (zh) | 2008-06-18 |
| US20080207599A1 (en) | 2008-08-28 |
| ZA200709048B (en) | 2008-09-25 |
| NO20075562L (no) | 2007-12-07 |
| BRPI0610038A2 (pt) | 2016-11-29 |
| AU2006240324A1 (en) | 2006-11-02 |
| JP2008536921A (ja) | 2008-09-11 |
| EP1742639B1 (en) | 2012-01-04 |
| KR20080004615A (ko) | 2008-01-09 |
| ATE539755T1 (de) | 2012-01-15 |
| WO2006115743A2 (en) | 2006-11-02 |
| IL186641A0 (en) | 2008-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Meyers | Use of neurotransmitter precursors for treatment of depression | |
| Martin-Hernandez et al. | Chronic mild stress alters kynurenine pathways changing the glutamate neurotransmission in frontal cortex of rats | |
| Xiong et al. | Beneficial effects of (R)-ketamine, but not its metabolite (2R, 6R)-hydroxynorketamine, in the depression-like phenotype, inflammatory bone markers, and bone mineral density in a chronic social defeat stress model | |
| JP2023171776A (ja) | 成人における焦点てんかんの処置のための合成経皮的カンナビジオール | |
| EA200700500A1 (ru) | Совокупность лекарственных форм и способ её введения | |
| KR20120000560A (ko) | 아미노피리딘을 사용한 연장 요법을 위한 조성물 및 방법 | |
| Shokri et al. | Adjuvant use of melatonin for relieving symptoms of painful diabetic neuropathy: results of a randomized, double-blinded, controlled trial | |
| CN107949379A (zh) | L‑4‑氯代犬尿氨酸的治疗用途 | |
| AU780817B2 (en) | Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone | |
| RU2007143053A (ru) | Применение селективных модуляторов хлорных каналов для лечения алкогольной и/или стимуляторной токсикомании | |
| CN115605195A (zh) | 用于治疗大麻使用病症和缓解大麻素戒断的方法和组合物 | |
| KR20100038120A (ko) | 신경퇴행성 장애의 치료를 위한 신규한 네라멕산 조합물 | |
| Sechi et al. | Levetiracetam in stiff-person syndrome | |
| JP2024535585A (ja) | 脳内５－ヒドロキシトリプタミンの機能を治療目的で最適化する方法 | |
| Frattola et al. | Effects of alpidem in anxious elderly outpatients: a double-blind, placebo-controlled trial | |
| JP2025516328A (ja) | 疼痛を治療するための組成物および方法 | |
| Ito et al. | Paroxysmal hypertensive crises induced by selegiline in a patient with Parkinson's disease | |
| WO2022235576A1 (en) | Methods and compositions for treating depression | |
| TW201536277A (zh) | 苯甲酸鹽用於製備預防或治療失智症或輕度認知障礙之組成物的用途 | |
| US20190117634A1 (en) | Treatment of Vulvodynia | |
| JP2008536921A5 (https=) | ||
| US20230149392A1 (en) | Treatment of major depressive disorder | |
| US12539323B2 (en) | Anti-psychotic composition and treatment methods | |
| US20240350433A1 (en) | Treatment compositions and methods | |
| US8124594B2 (en) | Methods using phosphatidylserine, lysophosphatidylserine, and/or salts thereof to increase testosterone levels |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20100701 |